118 related articles for article (PubMed ID: 10083861)
21. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
Treskes M; Holwerda U; Klein I; Pinedo HM; van der Vijgh WJ
Biochem Pharmacol; 1991 Nov; 42(11):2125-30. PubMed ID: 1659819
[TBL] [Abstract][Full Text] [Related]
22. Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Kohara H; Tabata M; Kiura K; Ueoka H; Kawata K; Chikamori M; Aoe K; Chikamori K; Matsushita A; Harada M
Clin Cancer Res; 2002 Jan; 8(1):287-92. PubMed ID: 11801571
[TBL] [Abstract][Full Text] [Related]
23. Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells.
Poulain L; Sichel F; Crouet H; Bureau F; Gauduchon P; Gignoux M; Le Talaër JY
Cancer Chemother Pharmacol; 1997; 40(5):385-90. PubMed ID: 9272114
[TBL] [Abstract][Full Text] [Related]
24. Role of carbonate in the cytotoxicity of carboplatin.
Di Pasqua AJ; Goodisman J; Kerwood DJ; Toms BB; Dubowy RL; Dabrowiak JC
Chem Res Toxicol; 2007 Jun; 20(6):896-904. PubMed ID: 17497898
[TBL] [Abstract][Full Text] [Related]
25. Evaluation for Synergistic Effects by Combinations of Photodynamic Therapy (PDT) with Temoporfin (mTHPC) and Pt(II) Complexes Carboplatin, Cisplatin or Oxaliplatin in a Set of Five Human Cancer Cell Lines.
Lange C; Bednarski PJ
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332729
[TBL] [Abstract][Full Text] [Related]
26. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
Jones M; Siracky J; Kelland LR; Harrap KR
Br J Cancer; 1993 Jan; 67(1):24-9. PubMed ID: 8427780
[TBL] [Abstract][Full Text] [Related]
27. Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines.
Perez RP; O'Dwyer PJ; Handel LM; Ozols RF; Hamilton TC
Int J Cancer; 1991 May; 48(2):265-9. PubMed ID: 2019469
[TBL] [Abstract][Full Text] [Related]
28. [Platinum salts: cytotoxic mechanisms of action, mechanisms of resistance of cancer cells, interactions with ionizing radiation, specificity of carboplatin].
Rixe O
Bull Cancer; 2000 Aug; 87 Spec No():7-15. PubMed ID: 11082717
[TBL] [Abstract][Full Text] [Related]
29. [Additive effects of carboplatin (CBDCA) and Co-60 gamma rays in human tumor cells in vitro].
Flentje M; Latz D; Haner U; Hör A; Trinh S; Wannenmacher M
Strahlenther Onkol; 1991 Apr; 167(4):244-9. PubMed ID: 2028403
[TBL] [Abstract][Full Text] [Related]
30. Equivalence of pulsed-dose-rate to low-dose-rate irradiation in tumor and normal cell lines.
Niedbala M; Alsbeih G; Ng CE; Raaphorst GP
Radiat Res; 2001 Feb; 155(2):297-303. PubMed ID: 11175664
[TBL] [Abstract][Full Text] [Related]
31. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
32. Development of an in vitro chemo-radiation response assay for cervical carcinoma.
Monk BJ; Burger RA; Parker R; Radany EH; Redpath L; Fruehauf JP
Gynecol Oncol; 2002 Nov; 87(2):193-9. PubMed ID: 12477451
[TBL] [Abstract][Full Text] [Related]
33. Radiosensitization in vitro by cis-diammine (1,1-cyclobutanedicarboxylato) platinum(II) (carboplatin, JM8) and ethylenediammine-malonatoplatinum(II) (JM40).
Begg AC; van der Kolk PJ; Emondt J; Bartelink H
Radiother Oncol; 1987 Jun; 9(2):157-65. PubMed ID: 3303163
[TBL] [Abstract][Full Text] [Related]
34. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers.
Alberts DS; Fanta PT; Running KL; Adair LP; Garcia DJ; Liu-Stevens R; Salmon SE
Cancer Chemother Pharmacol; 1997; 39(6):493-7. PubMed ID: 9118460
[TBL] [Abstract][Full Text] [Related]
35. Functional and transcriptomic characterization of carboplatin-resistant A2780 ovarian cancer cell line.
Viscarra T; Buchegger K; Jofre I; Riquelme I; Zanella L; Abanto M; Parker AC; Piccolo SR; Roa JC; Ili C; Brebi P
Biol Res; 2019 Mar; 52(1):13. PubMed ID: 30894224
[TBL] [Abstract][Full Text] [Related]
36. Establishment and characterization of an acquired cisplatin-resistant subline in a human osteosarcoma cell line.
Asada N; Tsuchiya H; Ueda Y; Tomita K
Anticancer Res; 1998; 18(3A):1765-8. PubMed ID: 9673402
[TBL] [Abstract][Full Text] [Related]
37. Chemosensitivity and radiosensitivity of small cell lung cancer cell lines studied by a newly developed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) hybrid assay.
Hida T; Ueda R; Takahashi T; Watanabe H; Kato T; Suyama M; Sugiura T; Ariyoshi Y; Takahashi T
Cancer Res; 1989 Sep; 49(17):4785-90. PubMed ID: 2547517
[TBL] [Abstract][Full Text] [Related]
38. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
Donnelly ET; Kelley M; Rockwell S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):43-50. PubMed ID: 14574460
[TBL] [Abstract][Full Text] [Related]
39. Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation.
Charest G; Paquette B; Fortin D; Mathieu D; Sanche L
J Neurooncol; 2010 Apr; 97(2):187-93. PubMed ID: 19760366
[TBL] [Abstract][Full Text] [Related]
40. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]